临床与病理杂志2024，Vol.44Issue(5)：771-775,5.DOI:10.11817/j.issn.2095-6959.2024.230675
维奈克拉致Ph样急性淋巴细胞白血病肿瘤溶解综合征1例
Venetoclax induced Ph-like acute lymphoblastic leukemia tumor lysis syndrome:A case report
摘要
Abstract
Venetoclax is a selective B-cell lymphoma-2(Bcl-2)inhibitor,widely used in the treatment of hematologic malignancies with good efficacy.Its primary adverse effects include cytopenias,infections,gastrointestinal reactions,and electrolyte disturbances,with the potential for severe tumor lysis syndrome in chronic lymphocytic leukemia.The patient,a 75-year-old male,was admitted to Baoding No.1 Hospital on January 6,2023,with a diagnosis of refractory relapsed Ph-like acute lymphoblastic leukemia.Tumor lysis syndrome with acute renal failure,hyperkalemia,hypocalcemia,oliguria,hyperuricemia,and rapid onset of severe cytopenia and neutropenia occurred 3.5 hours after administering 100 mg of venetoclax.Despite symptomatic and supportive treatment leading to the recovery of renal function,the patient continued to experience persistent pancytopenia with severe infections and ultimately died.关键词
急性淋巴细胞白血病/肿瘤溶解综合征/维奈克拉Key words
acute lymphoblastic leukemia/tumor lysis syndrome/venetoclax引用本文复制引用
丁月玲,成志勇,付建珠,李宗英,丁玉芝,柳倩..维奈克拉致Ph样急性淋巴细胞白血病肿瘤溶解综合征1例[J].临床与病理杂志,2024,44(5):771-775,5.基金项目
河北省重点研发计划项目(223777105D) （223777105D）
保定市科技计划项目(2341ZF232).This work was supported by the Key Research and Development Project of Hebei Province(223777105D)and Baoding Science and Technology Plan Project(2341ZF232),China. （2341ZF232）
